Recently, tobacco consumption has soared, particularly in developing countries. According to the World Health Organization (WHO), the tobacco epidemic is one of the biggest public health threats the world has ever faced, killing over 7 million people a year. Over 6 million of those deaths are the result of direct tobacco use, while around 890.000 result from passive exposure to tobacco smoke \[[@ref1]\].

Although tobacco consumption occurs mainly in the form of cigarette smoking, other smokeless forms of tobacco usage are also prevalent. Smokeless tobacco is used by many cultures all over the world, including the United States, Sweden, India, and the Middle East \[[@ref2]--[@ref5]\]. Some commonly used smokeless tobacco products include chewing tobacco, snuff, snus, and topical tobacco paste \[[@ref4]\]. In Turkey, the most common smokeless tobacco product is maras powder, a snus-like product that is used by compressing a powder-filled mini bag in the buccal mucosa between the teeth and lips \[[@ref6]\]. Maras powder is obtained from a plant called Nicotina rustica linn. The nicotine content of this plant is 6--10 times higher than that of Nicotina tobacum, which cigarettes are produced from \[[@ref7]\].

The prevalence of smoking in Turkey is well-known. According to WHO data, the age-standardized estimated prevalence of people aged 15 years or more ever having smoked tobacco is 41.6% for men and 13.2% for women. The health effects of cigarette smoking \[[@ref8]\], its role in carcinogenesis \[[@ref9]\], and its respiratory symptomatology \[[@ref10]\] have been examined in detail in the literature. However, to the best of our knowledge, to date there is no study on the symptomatology of smokeless tobacco use in Turkey \[[@ref11]\].

In light of this knowledge gap, we aimed to investigate the relationship between the use of smokeless tobacco and the related otorhinolaryngological symptoms in Kahramanmaras, the city that gives the smokeless tobacco product maras powder its name, and where its usage is extremely common.

MATERIALS AND METHODS {#sec1-2}
=====================

Study Design {#sec2-1}
------------

This descriptive study was carried out in Kahramanmaras, Turkey in 2016. A questionnaire consisting of 45 questions was administered to the participants. The first 9 questions were regarding the socio-demographic characteristics and the rest of the questions were related to otorhinolaryngological symptoms and smokeless tobacco consumption.

Data Collection {#sec2-2}
---------------

At total of 299 (49.9%) patients aged over 18 years who applied to the Department of Otorhinolaryngology polyclinic between April 2016 and September 2016 and who consumed smokeless tobacco 3 times or more per day for at least 5 years were included in the study as the smokeless tobacco user group. A total of 300 (50.1%) healthy volunteers, who did not use tobacco or its products and demonstrated similarities to the smokeless tobacco user group in terms of age, gender, and certain socio-demographic characteristics formed the non-tobacco user group.

The participants with upper respiratory tract infections and chronic respiratory system diseases such as chronic obstructive pulmonary disease and asthma were excluded from the study. The smokeless tobacco user group enrolled only those who did not have an obvious pathological explanation for their symptoms. The non-tobacco user group included healthy individuals who had no health problems.

Each member of both groups filled and signed the detailed questionnaire form that queried socio-demographic characteristics and otorhinolaryngological symptoms.

Statistical Analysis {#sec2-3}
--------------------

Data were analyzed using the SPSS statistical software version 22. Symptoms and socio-demographic variables were presented as frequencies and percentages in tables. The Pearson chi-square test and Student's t-test were applied to assess the results. The level of statistical significance was accepted as p\<0.05 and the estimated odds ratios (OR) were presented with a 95% confidence interval.

Ethical Considerations {#sec2-4}
----------------------

The study was approved by the Local Scientific Research Ethics Committee. Written informed consent was obtained from all participants, and their participation in the study was purely voluntary.

RESULTS {#sec1-3}
=======

A total of 599 participants were included in the research. Of these, 299 had used smokeless tobacco for at least 5 years prior to the study and the remaining 300 people were not tobacco users. The distribution of some socio-demographic factors such as age, gender, marital status, education, economic status, and place of settlement of the groups are shown in [Table 1](#T1){ref-type="table"}. There were no differences between the groups in terms of age, gender, marital status, education, economic status, and place of settlement (p\>0.05).

###### 

Comparison of smokeless tobacco users and non-tobacco users according to social demographic characteristics

  Socio-demographic characteristics   Smokeless tobacco users   Non-tobacco users   p                   
  ----------------------------------- ------------------------- ------------------- ----- ------------- -----------
  Age                                                           36.80±15.42               38.92±14.44   **0.123**
  Gender                                                                                                
   Female                             24                        38.7                38    61.3          **0.062**
   Male                               275                       51.2                262   48.8          
  Marital status                                                                                        
   Married                            198                       47.3                221   52.7          **0.055**
   Single                             91                        58.3                65    41.7          
   Divorced                           8                         44.4                10    55.6          
  Education                                                                                             
   Illiterate                         6                         35.3                11    64.7          **0.091**
   Literate                           22                        61.1                14    38.9          
   Elementary school                  82                        54.7                68    45.3          
   Middle school                      38                        44.7                47    55.3          
   High school                        101                       53.4                88    46.6          
   University                         49                        41.9                68    58.1          
  Economic status                                                                                       
   Low                                49                        41.5                69    58.5          **0.080**
   Moderate                           220                       52.9                196   47.1          
   High                               26                        46.4                30    53.6          
  Settlement place                                                                                      
   Village                            36                        61.0                23    39.0          **0.100**
   District                           50                        43.9                64    56.1          
   City                               210                       50.4                207   49.6          

Row percentage.

Comparison of smokeless tobacco users and non-tobacco users according to upper respiratory tract symptoms is shown in [Table 2](#T2){ref-type="table"}. Cough, sputum, shortness of breath, dysphagia, snoring, and apnea-hypopnea were found to be significantly increased in smokeless tobacco users (p\<0.05). There were no significant differences between the groups in terms of hoarseness, reflux, neck pain, swelling in the neck, and pruritus (p=0.031, p=0.938, p=0.785, p=0.879, p=0.287 respectively). The highest odds ratio found was for sputum at 2.615.

###### 

Comparison of smokeless tobacco users and non-tobacco users according to upper respiratory tract symptoms

  Upper respiratory tract symptoms   Smokeless tobacco users users   Non-tobacco   x²    p      OR                    
  ---------------------------------- ------------------------------- ------------- ----- ------ ------- ------------- --------------------------
  Cough                                                                                                               
   Yes                               111                             60.7          72    39.3   12.17   **\<0.001**   **1.871** (1.313--2.667)
   No                                187                             45.2          227   54.8                         
  Sputum                                                                                                              
   Yes                               127                             65.8          66    34.2   28.55   **\<0.001**   **2.615** (1.829--3.738)
   No                                170                             42.4          231   57.6                         
  Hoarseness                                                                                                          
   Yes                               62                              53.4          54    46.6   0.62    0.031         --
   No                                237                             49.4          243   50.6                         
  Shortness of breath                                                                                                 
   Yes                               99                              59.3          68    40.7   7.99    **\<0.005**   **1.683** (1.171--2.418)
   No                                199                             46.4          230   53.6                         
  Reflux                                                                                                              
   Yes                               85                              50.0          85    50.0   0.00    0.938         --
   No                                213                             50.4          210   49.6                         
  Dysphagia                                                                                                           
   Yes                               65                              60.7          42    39.3   6.43    **0.011**     **1.733** (1.130--2.657)
   No                                226                             47.2          253   52.8                         
  Snore                                                                                                               
   Yes                               155                             55.6          124   44.4   6.87    **0.009**     **1.540** (1.115--2.129)
   No                                142                             42.8          175   52.2                         
  Apnea hypopnea                                                                                                      
   Yes                               68                              63.0          40    37.0   8.75    **0.003**     **1.900** (1.237--2.918)
   No                                230                             47.2          257   52.8                         
  Neck pain                                                                                                           
   Yes                               82                              49.1          85    50.9   0.07    0.785         --
   No                                217                             50.3          214   49.7                         
  Swelling in the neck                                                                                                
   Yes                               24                              51.1          23    48.1   0.02    0.879         --
   No                                275                             49.9          276   50.1                         
  Pruritus                                                                                                            
   Yes                               46                              55.4          37    44.6   1.13    0.287         --
   No                                253                             49.1          262   50.9                         

Pearson Chi-Square Test; α: 0.05.

Comparison of groups regarding oral cavity symptoms is shown in [Table 3](#T3){ref-type="table"}. Mouth tickling, dryness of throat, mouth sores, halitosis, taste disorders, and toothache were found to be significantly increased in smokeless tobacco users (p\<0.05). It is noteworthy that halitosis was 9.4 times more among smokeless tobacco users than among the non-tobacco users. However, there were no differences between the groups in terms of sore throat, throat stinging, and gingival bleeding (p=0.187, p=0.790, p=0.424 respectively).

###### 

Comparison of smokeless tobacco users and non-tobacco users according to oral cavity symptoms

  Oral cavity symtoms   Smokeless tobacco users users   Non-tobacco   x²    p      OR                     
  --------------------- ------------------------------- ------------- ----- ------ -------- ------------- ---------------------------
  Mouth tickling                                                                                          
   Yes                  114                             69.1          51    30.9   33.94    **\<0.001**   **3.038** (2.074--4.451)
   No                   181                             42.4          246   57.2                          
  Dryness of throat                                                                                       
   Yes                  168                             66.4          85    33.6   48.84    **\<0.001**   **3.304** (2.351--4.645)
   No                   128                             37.4          214   62.6                          
  Sore throat                                                                                             
   Yes                  87                              54.4          73    45.6   1.73     0.187         --
   No                   211                             48.3          226   51.7                          
  Throat stinging                                                                                         
   Yes                  61                              50.8          59    49.2   0.07     0.790         --
   No                   236                             49.5          241   50.5                          
  Mouth sores                                                                                             
   Yes                  56                              62.2          34    37.8   6.50     **0.011**     **1.810** (1.143--2.869)
   No                   242                             47.6          266   52.4                          
  Halitosis                                                                                               
   Yes                  226                             75.1          75    24.9   154.56   **\<0.001**   **9.417** (6.489--13.665)
   No                   72                              24.2          225   75.8                          
  Taste disorders                                                                                         
   Yes                  75                              63.3          43    36.4   11.08    **\<0.001**   **2.010** (1.327--3.046)
   No                   223                             46.5          257   53.5                          
  Toothache                                                                                               
   Yes                  111                             56.6          85    43.4   5.26     **0.022**     **1.494** (1.060--2.108)
   No                   187                             46.6          214   53.4                          
  Gingival bleeding                                                                                       
   Yes                  111                             52.1          102   47.9   0.63     0.424         --
   No                   187                             48.7          197   51.3                          

Pearson Chi-Square Test; α: 0.05.

Comparison of smokeless tobacco users and non-tobacco users according to sinonasal symptoms is shown in [Table 4](#T4){ref-type="table"}. Sneezing, headache, facial fullness, and anorexia were found to be significantly increased in smokeless tobacco users (p\<0.05). There were no significant differences between the groups in terms of runny nose, nasal bleeding, postnasal drainage, and nausea (p=0.134, p=0.345, p=0.475, p=0.084 respectively).

###### 

Comparison of smokeless tobacco users and non-tobacco users according to sinonasal symptoms

  Sinonasal symtoms    Smokeless tobacco users users   Non-tobacco   x²    p      OR                  
  -------------------- ------------------------------- ------------- ----- ------ ------- ----------- --------------------------
  Runny nose                                                                                          
   Yes                 89                              54.9          73    45.3   2.24    0.134       --
   No                  210                             48.1          227   50.9                       
  Nasal bleeding                                                                                      
   Yes                 36                              45.0          44    55.0   0.89    0.345       --
   No                  263                             50.7          256   49.3                       
  Sneeze                                                                                              
   Yes                 157                             54.9          129   45.1   5.25    **0.022**   **1.457** (1.056--2.011)
   No                  142                             45.5          170   54.5                       
  Postnasal drainage                                                                                  
   Yes                 69                              52.7          62    47.3   0.51    0.475       --
   No                  229                             49.1          237   50.9                       
  Smell disorders                                                                                     
   Yes                 56                              57.1          42    42.9   2.33    0.126       --
   No                  243                             48.7          256   51.3                       
  Headache                                                                                            
   Yes                 150                             54.5          125   45.5   4.35    **0.037**   **1.409** (1.021--1.946)
   No                  149                             46.0          175   54.0                       
  Facial fullness                                                                                     
   Yes                 58                              59.2          40    40.8   4.02    **0.045**   **1.564** (1.008--2.427)
   No                  241                             48.1          260   51.9                       
  Nausea                                                                                              
   Yes                 71                              56.8          54    43.2   2.99    0.084       --
   No                  228                             48.1          246   51.9                       
  Anorexia                                                                                            
   Yes                 97                              61.8          60    38.2   12.00   **0.001**   **1.922** (1.324--2.790)
   No                  201                             45.7          239   54.3                       

Pearson Chi-Square Test; α: 0.05.

Comparison of groups regarding ear symptoms is shown in [Table 5](#T5){ref-type="table"}. There were no differences between the groups in terms of hearing loss, dizziness, ear disorders, ear fullness, and tinnitus (p=0.310, p=0.185, p=0.248, p=0.330, p=0.586 respectively).

###### 

Comparison of smokeless tobacco users and non-tobacco users according to ear symptoms

  Ear symtoms     Smokeless tobacco users   Non-tobacco users   x²    p      OR             
  --------------- ------------------------- ------------------- ----- ------ ------ ------- ----
  Hearing loss                                                                              
   Yes            53                        54.6                44    45.4   1.03   0.310   --
   No             246                       49.0                256   51.0                  
  Dizziness                                                                                 
   Yes            91                        54.2                77    45.8   1.75   0.185   --
   No             207                       48.1                223   51.9                  
  Ear disorders                                                                             
   Yes            46                        44.7                57    55.3   1.33   0.248   --
   No             252                       50.9                243   49.1                  
  Ear fullness                                                                              
   Yes            33                        55.9                26    44.1   0.94   0.330   --
   No             266                       49.3                274   50.7                  
  Tinnitus                                                                                  
   Yes            88                        51.8                82    48.2   0.29   0.586   --
   No             211                       49.3                217   50.7                  

Pearson Chi-Square Test; α: 0.05.

DISCUSSION {#sec1-4}
==========

Maras powder is obtained from a plant that has a higher nicotine content than the plants that are used in regular cigarette production. It is mostly consumed in Kahramanmaras and Gaziantep, cities located in the Southeastern Region of Turkey. There is a misguided public opinion that the use of maras powder does not carry the same detrimental health effects as cigarette smoking. On the contrary, studies show that maras powder can cause many systemic diseases in humans \[[@ref12]--[@ref14]\]. Consumption of maras powder causes genotoxic, mutagenic, and carcinogenic effects, particularly due to the *N*-nitrosamines in its content.

There is much evidence that nicotine is a major immunosuppressant. Nicotine induces ACTH secretion, which releases catecholamines that have suppressive effects on the immune system \[[@ref15]\]. This leads to the emergence of clinical symptoms, which are indicators of several diseases. Smoking also causes changes in the mucus production mechanism. Chronic exposure to smoke increases the number and size of goblet cells, resulting in metaplastic changes in the respiratory mucosa and a consequent increase in upper respiratory secretion \[[@ref16], [@ref17]\]. Although there are many studies in the literature about the effect of cigarette smoking on the upper respiratory tract, there is limited research on the effects of smokeless tobacco. In a study which the effect of local herbal tobacco use on pulmonary function was assessed, pulmonary dysfunction was determined in chronic consumption and symptoms such as coughing were reported to be high \[[@ref18]\]. Another study \[[@ref19]\] reported a higher risk of chronic bronchitis in smokeless tobacco users. Even though the systemic effects of maras powder taken orally are different from the direct effects of cigarette smoke, we found that cough, sputum, and shortness of breath were significantly higher among the smokeless tobacco users than the non-tobacco users. We agreed that these symptoms paved the way for pulmonary disorders in the future.

In chronic voice disorders, the negative effect of cigarette smoke on vocal cords is a known fact. However, as expected, we found that smokeless tobacco did not have any effect on voice morbidity. Smoking negatively affects the gastroesophageal reflex and pharyngeal swallowing reflex \[[@ref20], [@ref21]\] and may cause dysphagia and respiratory complications due to gastroesophageal reflux. Aro et al. \[[@ref22]\] found that smokeless tobacco significantly changes the histology of the distal esophagus but does not lead to gastrointestinal symptoms or peptic ulcers. In our study, the rate of reflux symptoms was similar in both groups. However, dysphagia was found to be higher among smokeless tobacco users.

Due to its high nicotine content, sleepiness tends to increase during the day in people using smokeless tobacco. Studies have shown that there is a synergistic effect between smoking and snoring, and smoking increases the risk of cardiovascular disease with both oxidative stress and endothelial dysfunction through abnormal inflammatory response \[[@ref12], [@ref13], [@ref23]\]. In our study, snoring and apnea-hypopnea rates were higher in smokeless tobacco users.

Over 700 species of bacteria have been identified in the human oral cavity \[[@ref24], [@ref25]\]. These bacteria play a role in both oral and systemic health. One of the causes of halitosis is the deterioration of the bacterial flora. These bacteria cause oral malodor by producing various substances such as sulfur compounds, diamines, and short chain fatty acids \[[@ref26], [@ref27]\]. Keene and Johnson \[[@ref28]\] found that *Streptococcus mutans* (*S. mutans*) increases in the oral mucosa due to increased nicotine. Increased levels of nicotine in saliva have been thought to stimulate the colonization of *S. mutans* and increase the risk of oral carriage. In our study, the most notable of the oral symptoms in smokeless tobacco users was halitosis. In an in vitro study, it was found that the number of fibroblasts and the amount of gingiva type 1 collagen increased with nicotine use \[[@ref29]\], which indicates that nicotine causes fibrosis in the oral mucosa. As a matter of fact, we found that mouth tickling, dryness of throat, throat stinging, taste disorders, and toothache were higher among smokeless tobacco users. These findings suggest that smokeless tobacco consumption may lead to a deterioration of the oral flora and a rise in the risk of infection.

Smokeless tobacco may cause hyperkeratotic lesions, periodontal diseases and intra-oral premalignant lesions in the oral mucosa. It also chronically stimulates the lymphoid tissue in the oral mucosa and consequently raises the risk of gingivitis, erythroplakia, leukoplakia, submucous fibrosis, and lichen planus. Epidemiological and experimental studies have shown a strong association between oral and pharyngeal cancers and smokeless tobacco \[[@ref30], [@ref31]\]. Dodani et al. \[[@ref32]\] found pathological findings in mucosa as a result of direct exposure of gingiva to various toxic chemicals. In previous studies, epithelial anomalies and precancerous lesions were determined from biopsies of gingival tissues of maras powder users \[[@ref6], [@ref33]\]. With increased nicotine-induced vasoconstriction, the gingival keratinization increases, as a result of which smokers are prone to less gingival bleeding. Although we found a higher number of mouth sores in smokeless tobacco users, gingival bleeding and sore throat were not different from the non-tobacco users.

Epidemiological studies suggest a correlation between exposure to tobacco smoke and rhinosinusitis. Goldstein-Daruech et al. \[[@ref34]\] found that exposure to tobacco led the formation of a synonasal biofilm and contributed to the conversion of a transient and medically treatable infection to a tenacious and therapeutic persistent state. Mahakit et al. \[[@ref35]\] showed that cigarette smoking negatively affects the mucociliary function. Sanli et al. \[[@ref36]\] found that while nasal obstruction, malodor, and snoring were significantly higher in smokers, symptoms such as nasal discharge, sneezing, nasal discharge, and headache were similar to the control group. In our study, while sneezing, headache, facial fullness, and anorexia were higher in smokeless tobacco users, the rates of runny nose, nasal bleeding, post nasal drainage, and smell disorders were similar in both groups. These results suggest that the negative effects of cigarette smoke on nasal function are higher than smokeless tobacco.

Gaur et al. \[[@ref37]\] found that smokers had more otological diseases. Sanli et al. \[[@ref36]\] found that ear discharge, hearing loss, dizziness, and tinnitus were more common in smokers. While there are many studies in the literature proving that cigarette disrupts cochlear function, not many studies on the effect of smokeless tobacco on the ear have been researched \[[@ref37]--[@ref39]\]. In our study, we found equal rates of ear symptoms in both groups. However, we believe that there is a need for more extensive research in this regard.

Strengths and Limitations {#sec2-5}
-------------------------

A strength of the present study was that it was conducted in a city where smokeless tobacco consumption is prevalent. Another strength was that the study population was relatively large.

However, there were several limitations. First, the study was carried out on the applicants of a hospital, which hinders extrapolation of the results to the general population. Second, the duration of smokeless tobacco presence in the oral cavity was not questioned, therefore, the dose-response relationship between the usage habit and symptoms could not be assessed. Lastly, as this was a survey study, the inconsistencies in patients' memory may have affected the responses to the questionnaire.

CONCLUSION {#sec1-5}
==========

Our study revealed that the effect of smokeless tobacco on the oral cavity was excessive and that there was no difference between the groups in terms of any ear symptoms. We found that smokeless tobacco users had significant potential clinical symptoms compared to non-tobacco users, which are premonitors of several diseases. By the elimination of the etiology that causes the symptoms and by performing screening for the emerged symptoms, the disease may be prevented. Thus, preventive medicine should be brought to the forefront.
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